Albert Wolkerstorfer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7861223/publications.pdf

Version: 2024-02-01

131 131 131 4970 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. British Journal of Dermatology, 2007, 157, 645-648.	1.4	358
2	Guidelines for the management of vitiligo: the European Dermatology Forum consensus. British Journal of Dermatology, 2013, 168, 5-19.	1.4	328
3	Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nature Genetics, 2012, 44, 676-680.	9.4	293
4	A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. Nature Genetics, 2000, 26, 470-473.	9.4	249
5	Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. Nature Genetics, 2016, 48, 1418-1424.	9.4	225
6	An overview of clinical and experimental treatment modalities for port wine stains. Journal of the American Academy of Dermatology, 2012, 67, 289-304.e29.	0.6	179
7	Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners. British Journal of Dermatology, 2013, 168, 162-171.	1.4	140
8	Scoring the Severity of Atopic Dermatitis: Three Item Severity Score as a Rough System for Daily Practice and as a Pre-screening Tool for Studies. Acta Dermato-Venereologica, 1999, 79, 356-359.	0.6	132
9	Laser and intense pulsed light therapy for the treatment of hypertrophic scars: a systematic review. British Journal of Dermatology, 2011, 165, 934-942.	1.4	112
10	Development and Validation of the Vitiligo Extent Score (VES): an International Collaborative Initiative. Journal of Investigative Dermatology, 2016, 136, 978-984.	0.3	90
11	Efficacy and safety of wetâ€wrap dressings in children with severe atopic dermatitis: influence of corticosteroid dilution. British Journal of Dermatology, 2000, 143, 999-1004.	1.4	85
12	The prevalence of thyroid disease in patients with vitiligo: a systematic review. British Journal of Dermatology, 2012, 167, 1224-1235.	1.4	83
13	Hypertrophy in port-wine stains: Prevalence and patient characteristics in a large patient cohort. Journal of the American Academy of Dermatology, 2012, 67, 1214-1219.	0.6	76
14	Transcutaneous laser treatment of leg veins. Lasers in Medical Science, 2014, 29, 481-492.	1.0	66
15	Natural course of sensitization to cow's milk and hen's egg in childhood atopic dermatitis: ETACTM Study Group. Clinical and Experimental Allergy, 2002, 32, 70-73.	1.4	65
16	Nonâ€ablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: A randomized controlled splitâ€face study. Lasers in Surgery and Medicine, 2010, 42, 607-612.	1.1	64
17	Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: AÂrandomized controlled pilot study. Journal of the American Academy of Dermatology, 2011, 64, 516-523.	0.6	63
18	Efficacy and safety of fluticasone propionate 0.005% ointment in the longâ€term maintenance treatment of children with atopic dermatitis: Differences between boys and girls?. Pediatric Allergy and Immunology, 2009, 20, 59-66.	1.1	61

#	Article	IF	Citations
19	Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. Journal of the American Academy of Dermatology, 1998, 39, 226-231.	0.6	55
20	An Overview of Three Promising Mechanical, Optical, and Biochemical Engineering Approaches to Improve Selective Photothermolysis of Refractory Port Wine Stains. Annals of Biomedical Engineering, 2012, 40, 486-506.	1.3	54
21	Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo. British Journal of Dermatology, 2015, 172, 437-443.	1.4	51
22	Soluble Eâ€selectin, other markers of inflammation and disease severity in children with atopic dermatitis. British Journal of Dermatology, 1998, 138, 431-435.	1.4	50
23	Port wine stain treatment outcomes have not improved over the past three decades. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1369-1377.	1.3	48
24	A randomized comparison of excimer laser versus narrowâ€band ultraviolet B phototherapy after punch grafting in stable vitiligo patients. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 690-695.	1.3	47
25	Excimer laser vs. clobetasol propionate O·05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot. British Journal of Dermatology, 2010, 163, 823-831.	1.4	46
26	Navigating the landscape of core outcome set development in dermatology. Journal of the American Academy of Dermatology, 2019, 81, 297-305.	0.6	46
27	Spatiotemporal closure of fractional laserâ€ablated channels imaged by optical coherence tomography and reflectance confocal microscopy. Lasers in Surgery and Medicine, 2016, 48, 157-165.	1.1	44
28	Early-onset autoimmune vitiligo associated with an enhancer variant haplotype that upregulates class II HLA expression. Nature Communications, 2019, 10, 391.	5.8	43
29	Measurement Properties of Outcome Measures for Vitiligo. Archives of Dermatology, 2012, 148, 1302.	1.7	40
30	Development and validation of a patient-reported outcome measure in vitiligo: The Self Assessment Vitiligo Extent Score (SA-VES). Journal of the American Academy of Dermatology, 2017, 76, 464-471.	0.6	37
31	Diagnostic accuracy of confocal microscopy imaging vs. punch biopsy for diagnosing and subtyping basal cell carcinoma. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1641-1648.	1.3	35
32	Ablative fractional laser therapy as treatment for Becker nevus: A randomized controlled pilot study. Journal of the American Academy of Dermatology, 2011, 65, 1173-1179.	0.6	34
33	Provoking factors, including chemicals, in Dutch patients with vitiligo. British Journal of Dermatology, 2013, 168, 1003-1011.	1.4	28
34	Melanocyte antigenâ€specific antibodies cannot be used as markers for recent disease activity in patients with vitiligo. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 1172-1175.	1.3	26
35	Fractional CO ₂ laser assisted delivery of topical anesthetics: A randomized controlled pilot study. Lasers in Surgery and Medicine, 2016, 48, 208-211.	1.1	26
36	Long-term results of 2-mm punch grafting in patients with vitiligo vulgaris and segmental vitiligo: effect of disease activity. British Journal of Dermatology, 2009, 161, 1105-1111.	1.4	25

3

#	Article	IF	CITATIONS
37	Long-term remission of folliculitis decalvans after treatment with the long-pulsed Nd:YAG laser. Journal of Dermatological Treatment, 2014, 25, 167-168.	1.1	25
38	A Randomized Controlled Pilot Study on Ablative Fractional CO2 Laser for Consecutive Patients Presenting With Various Scar Types. Dermatologic Surgery, 2015, 41, 371-377.	0.4	25
39	Oneâ€stopâ€shop with confocal microscopy imaging vs. standard care for surgical treatment of basal cell carcinoma: an openâ€label, noninferiority, randomized controlled multicentre trial. British Journal of Dermatology, 2017, 177, 735-741.	1.4	25
40	Natural course of cow's milk allergy in childhood atopic eczema/dermatitis syndrome. Annals of Allergy, Asthma and Immunology, 2002, 89, 52-55.	0.5	24
41	Longâ€pulsed 1064 nm Nd:YAG laser improves hypertrophic portâ€wine stains. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 1381-1386.	1.3	24
42	High Prevalence of Autoimmune Thyroiditis in Children and Adolescents with Vitiligo. Hormone Research in Paediatrics, 2013, 79, 137-144.	0.8	24
43	Red tattoo reactions, a prospective cohort on clinical aspects. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e384-e386.	1.3	24
44	Reliability and validity of the Vitiligo Signs of Activity Score (VSAS). British Journal of Dermatology, 2020, 183, 883-890.	1.4	24
45	Laser treatment of congenital melanocytic naevi: a systematic review. British Journal of Dermatology, 2018, 178, 369-383.	1.4	23
46	The antibody response against <scp>MART</scp> â€1 differs in patients with melanomaâ€associated leucoderma and vitiligo. Pigment Cell and Melanoma Research, 2014, 27, 1086-1096.	1.5	22
47	Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the field. Journal of the American Academy of Dermatology, 2016, 75, 1198-1204.	0.6	22
48	Granulomatous tattoo reactions in permanent makeup of the eyebrows. Journal of Cosmetic Dermatology, 2019, 18, 212-214.	0.8	22
49	Treatment of erythrodermic atopic dermatitis with "wet-wrap―fluticasone propionate 0.05% cream/emollient 1:1 dressings. Journal of Dermatological Treatment, 1999, 10, 73-74.	1.1	20
50	Soluble E-selectin and soluble ICAM-1 levels as markers of the activity of atopic dermatitis in children. Pediatric Allergy and Immunology, 2003, 14, 302-306.	1.1	20
51	Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot study. Journal of Dermatological Treatment, 2012, 23, 339-344.	1.1	20
52	The Vitiligo Extent Score (VES) and the VESplus are responsive instruments to assess global and regional treatment response in patients with vitiligo. Journal of the American Academy of Dermatology, 2018, 79, 369-371.	0.6	20
53	Is a punch biopsy reliable in subtyping basal cell carcinoma? A systematic review. British Journal of Dermatology, 2016, 175, 401-403.	1.4	19
54	Autologous cell suspension grafting in segmental vitiligo and piebaldism: a randomized controlled trial comparing full surface and fractional CO ⟨sub⟩2⟨/sub⟩ laser recipientâ€site preparations. British Journal of Dermatology, 2017, 177, 1293-1298.	1.4	19

#	Article	IF	CITATIONS
55	Autologous cell suspension transplantation using a cell extraction device in segmental vitiligo and piebaldism patients: A randomized controlled pilot study. Journal of the American Academy of Dermatology, 2015, 73, 170-172.	0.6	18
56	Complications of tattoos and permanent makeup: overview and analysis of 308 cases. Journal of Cosmetic Dermatology, 2021, 20, 3630-3641.	0.8	18
57	Prospective analysis of the port-wine stain patient population in the Netherlands in light of novel treatment modalities. Journal of Cosmetic and Laser Therapy, 2018, 20, 77-84.	0.3	17
58	Reference method for digital surface measurement of target lesions in vitiligo: a comparative analysis. British Journal of Dermatology, 2019, 180, 1198-1205.	1.4	17
59	Standardizing serial photography for assessing and monitoring vitiligo: A core set of international recommendations for essential clinical and technical specifications. Journal of the American Academy of Dermatology, 2020, 83, 1639-1646.	0.6	17
60	Clinical outcome measures and scoring systems used in prospective studies of port wine stains: A systematic review. PLoS ONE, 2020, 15, e0235657.	1.1	17
61	Home vs. outpatient narrowband ultraviolet B therapy for the treatment of nonsegmental vitiligo: a retrospective questionnaire study. British Journal of Dermatology, 2010, 162, 1142-1144.	1.4	16
62	Low yield of routine screening for thyroid dysfunction in asymptomatic patients with vitiligo. British Journal of Dermatology, 2012, 166, 532-538.	1.4	15
63	Generalized eczematous reaction after fractional carbon dioxide laser therapy for tattoo allergy. Journal of Cosmetic and Laser Therapy, 2016, 18, 456-458.	0.3	15
64	Double Pass 595 nm pulsed dye laser at a 6 minute interval for the treatment of portâ€wine stains is not more effective than single pass. Lasers in Surgery and Medicine, 2012, 44, 199-204.	1.1	14
65	The validity, reliability and acceptability of the <scp>SAVASI</scp> ; a new selfâ€assessment score in vitiligo. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2145-2151.	1.3	14
66	Meeting report: Vitiligo Global Issues Consensus Conference Workshop "Outcome measurement instruments―and Vitiligo International Symposium, Rome, Nov 30–Dec 3rd. Pigment Cell and Melanoma Research, 2017, 30, 436-443.	1.5	14
67	The role of phototherapy in the surgical treatment of vitiligo: a systematic review. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1427-1435.	1.3	14
68	Parameters in fractional laser assisted delivery of topical anesthetics: Role of laser type and laser settings. Lasers in Surgery and Medicine, 2018, 50, 813-818.	1.1	14
69	Periocular CO ₂ laser resurfacing: severe ocular complications from multiple unintentional laser impacts on the protective metal eye shields. Lasers in Surgery and Medicine, 2018, 50, 980-986.	1.1	13
70	Laser treatment of epidermal nevi: A multicenter retrospective study with long-term follow-up. Journal of the American Academy of Dermatology, 2020, 83, 1606-1615.	0.6	13
71	Formation of Fibrosis After Nonablative and Ablative Fractional Laser Therapy. Dermatologic Surgery, 2012, 38, 437-442.	0.4	12
72	Q-switched laser depigmentation in vitiligo, most effective in active disease. British Journal of Dermatology, 2013, 169, 1246-1251.	1.4	12

#	Article	IF	CITATIONS
73	Optimising size and depth of punch grafts in autologous transplantation of vitiligo and piebaldism: a randomised controlled trial. Journal of Dermatological Treatment, 2017, 28, 86-91.	1.1	12
74	Validation study of the Vitiligo Extent Score-plus. Journal of the American Academy of Dermatology, 2018, 78, 1013-1015.	0.6	12
75	Punchgraft testing in vitiligo; effects of UVA, NBâ€UVB and 632.8â€ſnm Heliumâ€Neon laser on the outcome. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1236-1237.	1.3	11
76	UV light setâ€ups for vitiligo photography, a comparative study on image quality and ease of use. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1971-1975.	1.3	11
77	Protocol for the development of core set of domains of the core outcome set for patients with congenital melanocytic naevi (OCOMEN project). Journal of the European Academy of Dermatology and Venereology, 2020, 34, 267-273.	1.3	11
78	Ablative laser surgery for allergic tattoo reactions: a retrospective study. Lasers in Medical Science, 2021, 36, 1241-1248.	1.0	11
79	Patients' perspective on current treatments and demand for novel treatments in vitiligo. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 744-748.	1.3	11
80	Treatment of Basal Cell Carcinoma Using a One-Stop-Shop With Reflectance Confocal Microscopy: Study Design and Protocol of a Randomized Controlled Multicenter Trial. JMIR Research Protocols, 2015, 4, e109.	0.5	11
81	Assessing the dynamic changes in vitiligo: reliability and validity of the Vitiligo Disease Activity Score (<scp>VDAS</scp>) and Vitiligo Disease Improvement Score (<scp>VDIS</scp>). Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1334-1341.	1.3	11
82	Nonsegmental vitiligo disease duration and female sex are associated with comorbidity and disease extent: a retrospective analysis in 1307 patients aged ≥ 50 years. British Journal of Dermatology, 2016, 175, 821-824.	1.4	10
83	Validation of a physician global assessment tool for vitiligo extent: Results of an international vitiligo expert meeting. Pigment Cell and Melanoma Research, 2019, 32, 728-733.	1.5	10
84	Enhanced topical cutaneous delivery of indocyanine green after various pretreatment regimens: comparison of fractional CO2 laser, fractional Er:YAG laser, microneedling, and radiofrequency. Lasers in Medical Science, 2020, 35, 1357-1365.	1.0	10
85	Does autoimmune vitiligo protect against COVIDâ€19 disease?. Experimental Dermatology, 2021, 30, 1254-1257.	1.4	10
86	Clinical endpoints of needleâ€free jet injector treatment: An in depth understanding of immediate skin responses. Lasers in Surgery and Medicine, 2022, 54, 693-701.	1.1	10
87	Fractionated carbon dioxide laser therapy as treatment of mild rhinophyma: report of three cases. Dermatologic Therapy, 2015, 28, 147-150.	0.8	9
88	Drug penetration enhancement techniques in ablative fractional laser assisted cutaneous delivery of indocyanine green. Lasers in Surgery and Medicine, 2019, 51, 709-719.	1.1	9
89	Development of an international core domain set for medium, large and giant congenital melanocytic naevi as a first step towards a core outcome set for clinical practice and research*. British Journal of Dermatology, 2021, 185, 371-379.	1.4	9
90	Donor to recipient ratios in the surgical treatment of vitiligo and piebaldism: a systematic review. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1077-1086.	1.3	9

#	Article	IF	CITATIONS
91	Digital image analysis vs. clinical assessment to evaluate repigmentation after punch grafting in vitiligo. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e235-8.	1.3	8
92	The use of lasers in vitiligo, an overview. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 779-789.	1.3	8
93	Advances in the Treatment of Atopic Dermatitis with Special Regard to Children. , 1999, 28, 56-63.		7
94	Vitiligoâ€like depigmentations as the first sign of melanoma: a retrospective case series from a tertiary vitiligo centre. British Journal of Dermatology, 2017, 176, 503-506.	1.4	7
95	Electrosclerotherapy as a Novel Treatment Option for Hypertrophic Capillary Malformations: A Randomized Controlled Pilot Trial. Dermatologic Surgery, 2020, 46, 491-498.	0.4	7
96	Treatment Outcome Measurement Instruments for Port Wine Stains: A Systematic Review of Their Measurement Properties. Dermatology, 2021, 237, 416-432.	0.9	7
97	Domains and outcomes of the core outcome set of congenital melanocytic naevi for clinical practice and research (the OCOMEN project): part 2*. British Journal of Dermatology, 2021, 185, 970-977.	1.4	7
98	Focal vitiligo: longâ€ŧerm followâ€up of 52 cases. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1550-1554.	1.3	6
99	Twentyâ€year followâ€up using a postal survey of childhood vitiligo treated with narrowband ultraviolet B phototherapy. British Journal of Dermatology, 2017, 177, e60-e61.	1.4	6
100	Allergic Reaction to Red Cosmetic Lip Tattoo Treated With Hydroxychloroquine. Dermatitis, 2019, 30, 82-83.	0.8	6
101	Patient reported outcomes for intensified versus conventional NB-UVB treatment in non-segmental vitiligo. Journal of Dermatological Treatment, 2019, 30, 594-597.	1.1	6
102	Ultraviolet photography in vitiligo: image quality, validity and reliability. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1590-1594.	1.3	6
103	Assessing the minimal important change in the vitiligo extent score and the self-assessment vitiligo extent score. Journal of the American Academy of Dermatology, 2021, 85, 1363-1364.	0.6	6
104	Therapeutic Strategies for Untreated Capillary Malformations of the Head and Neck Region: A Systematic Review and Meta-Analyses. American Journal of Clinical Dermatology, 2021, 22, 603-614.	3.3	6
105	Extreme rises in serum alkaline phosphatase in children with atopic dermatitis after intervention treatment with cyclosporin A [letter]. Pediatric Dermatology, 1998, 15, 483-481.	0.5	6
106	Electrosclerotherapy for capillary malformations: study protocol for a randomised within-patient controlled pilot trial. BMJ Open, 2017, 7, e016401.	0.8	5
107	Tattoos and selfâ€reported adverse events in sarcoidosis patients. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e167-e169.	1.3	4
108	Validation of a Patient Global Assessment for extent, severity and impact to define the severity strata for the Self Assessment Vitiligo Extent Score (SAâ€VES). Journal of the European Academy of Dermatology and Venereology, 2021, 35, 216-221.	1.3	4

#	Article	IF	CITATIONS
109	Port-wine stain progression: is prevention by pulsed dye laser therapy possible?. European Journal of Dermatology, 2013, 23, 282-283.	0.3	3
110	Interrater and intrarater agreement of confocal microscopy imaging in diagnosing and subtyping basal cell carcinoma. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1278-1283.	1.3	3
111	The long road to valid outcomes in vitiligo. British Journal of Dermatology, 2019, 180, 454-455.	1.4	3
112	A systematic review of outcome reporting in laser treatments for dermatological diseases. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 47-53.	1.3	3
113	Generic outcome set for the international registry on Laser trEAtments in Dermatology (LEAD): a protocol for a Delphi study to achieve consensus on <i>what</i> to measure. BMJ Open, 2020, 10, e038145.	0.8	3
114	What is successful repigmentation in vitiligo from the point of view of patients?. British Journal of Dermatology, 2021, 184, 165-166.	1.4	3
115	Needleâ€free jet injectionâ€induced smallâ€droplet aerosol formation during intralesional bleomycin therapy. Lasers in Surgery and Medicine, 2022, 54, 572-579.	1.1	3
116	A core outcome domain set for clinical research on capillary malformations (the COSCAM project): an e-Delphi process and consensus meeting. British Journal of Dermatology, 2022, 187, 730-742.	1.4	3
117	Excimer laser: a treatment option for the prurigo form of atopic dermatitis. Expert Review of Dermatology, $2011, 6, 1-3$.	0.3	2
118	Development of a core outcome domain set for clinical research on capillary malformations (the) Tj ETQq0 0 0 rg 1888-1895.	BT /Overlo	ock 10 Tf 50 3 2
119	Meek micrografting: a novel surgical technique for the treatment of depigmentation. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e798-e801.	1.3	2
120	Timed exposure 10,600Ânm CO2 laser drilling in various benign dermal tumours. European Journal of Dermatology, 2015, 25, 358-359.	0.3	1
121	Patients' Perception of Vitiligo Severity. Acta Dermato-Venereologica, 2021, 101, adv00481.	0.6	1
122	Observations on CO ₂ laser preparation of recipient site for noncultured cell suspension transplantation in vitiligo. Journal of Cutaneous and Aesthetic Surgery, 2016, 9, 133.	0.2	1
123	P246 Fluticasone propionate once daily versus clobetasone butyrate twice daily in the treatment of atopic dermatitis in children. Journal of the European Academy of Dermatology and Venereology, 1997, 9, S209-S210.	1.3	0
124	Scoring atopic dermatitis. Journal of Dermatological Science, 1998, 16, S118.	1.0	0
125	Parameters in fractional laser assisted delivery of topical anesthetics: A randomized controlled study on the role of the anesthetic and application time. Journal of the American Academy of Dermatology, 2019, 80, 1132-1133.	0.6	0
126	Impact of graft cell density and viability on repigmentation upon noncultured autologous cell suspension transplantation in vitiligo and piebaldism. Clinical and Experimental Dermatology, 2020, 45, 907-908.	0.6	0

#	Article	IF	CITATIONS
127	Evidence for efficacy of homeâ€based narrowband ultraviolet B therapy. British Journal of Dermatology, 2021, 184, 790-790.	1.4	0